Natalia Kapelan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Natalia Kapelan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Adrianna Rutkowska
Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland
1 shared publication - Agata Budny-Lewandowska
Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland
1 shared publication - Agnieszka Szadkowska
Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, 91-738 Lodz, Poland
1 shared publication - Agnieszka Zmysłowska
Department of Clinical Genetics, Medical University of Lodz, 92-213 Lodz, Poland
1 shared publication - Damian Ciunowicz
Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland
1 shared publication - Edyta Budzyńska
Central Clinical Hospital of the Medical University of Lodz, 92-213 Lodz, Poland
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (10) , 199
The Clinical Spectrum and Significance of ABCC8 Gene Variants in the Diagnosis of Monogenic Diabetes
Background: ABCC8 gene variants have been linked to a range of conditions that affect insulin secretion, such as congenital hyperinsulinism, neonatal diabetes and maturity-onset diabetes of the young (MODY). This study aimed to characterise ABCC8 variants and to assess their relationship with clinical phenotypes and family segregation. Methods: Between 2017 and May 2026, tNGS (targeted next-generation sequencing) analysis was performed on the DNA of 1202 patients who were referred for suspected monogenic diabetes. The exons and flanking intronic regions of the ABCC8 gene were assessed for single nucleotide variants (SNVs) and small insertions and deletions (indels). Rare variants were prioritised based on population frequency, in silico predictions and clinical classification. Selected variants were confirmed, and segregation analysis was performed using Sanger sequencing. Results: We identified five patients carrying pathogenic or likely pathogenic ABCC8 variants. A frameshift ABCC8 variant had not been previously reported. All patients had diabetes, with some also presenting with a history of hypoglycaemia. Family studies also revealed intra-familial variability and enabled the identification of previously unrecognized affected relatives. Conclusions: Our findings support the broad clinical spectrum associated with ABCC8 variants and highlight the importance of family segregation analysis. Comprehensive molecular and clinical evaluation may improve the detection of patients with ABCC8-related diabetes and distinguish this condition from other forms of monogenic diabetes.
- 13 October 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (10) , 199
Open AccessThe Clinical Spectrum and Significance of ABCC8 Gene Variants in the Diagnosis of Monogenic Diabetes
Background: ABCC8 gene variants have been linked to a range of conditions that affect insulin secretion, such as congenital hyperinsulinism, neonatal diabetes and maturity-onset diabetes of the young (MODY). This study aimed to characterise ABCC8 variants and to assess their relationship with clinical phenotypes and family segregation. Methods: Between 2017 and May 2026, tNGS (targeted next-generation sequencing) analysis was performed on the DNA of 1202 patients who were referred for suspected monogenic diabetes. The exons and flanking intronic regions of the ABCC8 gene were assessed for single nucleotide variants (SNVs) and small insertions and deletions (indels). Rare variants were prioritised based on population frequency, in silico predictions and clinical classification. Selected variants were confirmed, and segregation analysis was performed using Sanger sequencing. Results: We identified five patients carrying pathogenic or likely pathogenic ABCC8 variants. A frameshift ABCC8 variant had not been previously reported. All patients had diabetes, with some also presenting with a history of hypoglycaemia. Family studies also revealed intra-familial variability and enabled the identification of previously unrecognized affected relatives. Conclusions: Our findings support the broad clinical spectrum associated with ABCC8 variants and highlight the importance of family segregation analysis. Comprehensive molecular and clinical evaluation may improve the detection of patients with ABCC8-related diabetes and distinguish this condition from other forms of monogenic diabetes.
- Open Access
CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
CRISPR–Cas9 has progressed from an experimental tool to a therapeutic modality, marked by the first regulatory approvals of an ex vivo-edited autologous CD34+ hematopoietic stem cell product that induces fetal hemoglobin (CASGEVY/exa-cel). In this narrative review, we synthesize modality-specific molecular diagnostic strategies used across early CRISPR clinical translation. In parallel, early clinical experience has begun to demonstrate the feasibility of in vivo editing, including subretinal delivery for CEP290-associated inherited retinal degeneration (EDIT-101 programme) and hepatocyte-targeted lipid nanoparticles (LNPs) for liver-derived targets such as transthyretin and plasma prekallikrein (KLKB1). As translation expands across hematologic, metabolic, ocular and oncology indications, development is increasingly constrained by the predictability and safety of editing outcomes, delivery-determined biodistribution and exposure time, and immune recognition of bacterial Cas9 orthologs and delivery components. We summarize diagnostic readouts for confirming patient genotype, quantifying on-target editing and expression changes, assessing off-target and structural outcomes using orthogonal assays, and monitoring clonal dynamics and immune responses during long-term follow-up. We also discuss how these readouts interface with CMC controls and regulatory expectations for advanced therapy medicinal products (ATMPs), highlighting the need for fit-for-purpose, standardized testing frameworks in early trials.
Open AccessCRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
CRISPR–Cas9 has progressed from an experimental tool to a therapeutic modality, marked by the first regulatory approvals of an ex vivo-edited autologous CD34+ hematopoietic stem cell product that induces fetal hemoglobin (CASGEVY/exa-cel). In this narrative review, we synthesize modality-specific molecular diagnostic strategies used across early CRISPR clinical translation. In parallel, early clinical experience has begun to demonstrate the feasibility of in vivo editing, including subretinal delivery for CEP290-associated inherited retinal degeneration (EDIT-101 programme) and hepatocyte-targeted lipid nanoparticles (LNPs) for liver-derived targets such as transthyretin and plasma prekallikrein (KLKB1). As translation expands across hematologic, metabolic, ocular and oncology indications, development is increasingly constrained by the predictability and safety of editing outcomes, delivery-determined biodistribution and exposure time, and immune recognition of bacterial Cas9 orthologs and delivery components. We summarize diagnostic readouts for confirming patient genotype, quantifying on-target editing and expression changes, assessing off-target and structural outcomes using orthogonal assays, and monitoring clonal dynamics and immune responses during long-term follow-up. We also discuss how these readouts interface with CMC controls and regulatory expectations for advanced therapy medicinal products (ATMPs), highlighting the need for fit-for-purpose, standardized testing frameworks in early trials.